Norges Bank
MGX icon

Norges Bank’s Metagenomi Therapeutics MGX Stock Holding History

Norges Bank’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-252,310
Closed -$373K – 1634
2025
Q2 		$373K Hold
252,310
– – ﹤0.01% 1652
2025
Q1 		$343K Sell
252,310
-107,892
-30% -$257K ﹤0.01% 1705
2024
Q4 		$1.3M Hold
360,202
– – ﹤0.01% 1730
2024
Q3 		$782K Hold
360,202
– – ﹤0.01% 1755
2024
Q2 		$1.47M Buy
360,202
+252,310
+234% +$1.73M ﹤0.01% 1771
2024
Q1 		$1.14M Buy
+107,892
New +$1.24M ﹤0.01% 1786

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Norges Bank's MGX Position: Q3 2025 in Review

Norges Bank sold out of Metagenomi Therapeutics (MGX) in Q3 2025, closing a stake of 252,310 shares — an estimated $373K sold.

Norges Bank first reported a position in MGX in Q1 2024 and held it in 6 quarters. The position peaked at $1.47M in Q2 2024. 58 funds tracked by Wall St. Rank hold MGX as of Q3 2025.

  • Norges Bank reported no remaining Metagenomi Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Norges Bank sold 252,310 Metagenomi Therapeutics shares in Q3 2025, an estimated $373K.
  • Norges Bank first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 6 quarters.
  • Norges Bank's Metagenomi Therapeutics position peaked at $1.47M in Q2 2024.
  • 58 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2025.

Based on Norges Bank's 13F filing for Q3 2025.